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11. Introduction
The WHO Expert Committee on Drug Dependence met in Geneva
from 17 to 20 September 2002. The meeting was opened by Dr L.
Rägo, Coordinator, Quality Assurance and Safety: Medicines, who
emphasized the signiﬁcant role this Committee has played in the
implementation of the international drug control system based on
the existing drug control conventions. As a specialized agency of the
United Nations system, WHO is responsible for conducting the medi-
cal and scientiﬁc evaluation of dependence-producing drugs and
makes recommendations to the Commission on Narcotic Drugs of the
United Nations concerning the level of international control to be
applied to them. As WHO has the sole responsibility for this function,
no drug can be controlled internationally without ﬁrst being evalu-
ated by WHO. The WHO Expert Committee on Drug Dependence
has been entrusted with the task of evaluating such drugs since WHO
was founded in 1948. Dr Rägo stressed the importance of balancing
the need for preventing diversion of therapeutic substances with
abuse potential by means of appropriate controls against the need for
ensuring access to these drugs for therapeutic use.
2. Scheduling criteria
In order to ensure consistency in the review process, WHO has devel-
oped a formal procedure for its review of dependence-producing
psychoactive substances. This procedure has been updated as the
need has arisen. The current review procedure follows the guidelines
(hereinafter referred to as “the Guidelines”) that were adopted by the
Executive Board of WHO in 2000 (1).
The scheduling criteria described in the Guidelines are based on the
relevant provisions of the international drug control conventions and
additional guiding principles worked out by this Committee at previ-
ous meetings. In essence, similarity in terms of abuse and ill effects
to drugs already controlled is the criterion applied to narcotic drugs.
In accordance with the 1961 Single Convention on Narcotic Drugs
(hereinafter referred to as “the 1961 Convention” (2)), the Expert
Committee, when deciding whether to recommend international con-
trol, ﬁrst determines whether the substance under review has mor-
phine-like, cocaine-like, or cannabis-like effects or is convertible into
a scheduled substance having such effects. If so, the Committee then
determines if the substance is liable to similar abuse and produces
similar ill effects to the substances in Schedule I or Schedule II, or
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2conﬁrms that it is convertible into a substance already in one of these
Schedules.
However, no speciﬁc guidance is given in the Guidelines as to how
similar to the original drug a substance must be for it to be considered
as morphine-like, cocaine-like or cannabis-like. The lack of speciﬁc
guidance on this matter poses considerable difﬁculty for the Commit-
tee when the drug under review has some similarity for example to
both a narcotic drug and a psychotropic substance, because the sched-
uling criteria in the 1971 Convention on Psychotropic Substances (3)
(hereinafter referred to as “the 1971 Convention”) also includes a
similarity rule. The decision as to whether to control analgesic and
stimulant drugs under the 1961 or 1971 Convention is a major prob-
lem. Most potent analgesics are controlled under the 1961 Conven-
tion, but a few are controlled as psychotropic substances under the
1971 Convention. Of the stimulants of the central nervous system,
cocaine is under the 1961 Convention, whereas amphetamines are
under the 1971 Convention. Thus, the criteria for choosing between
the two Conventions are ambiguous for these classes of drug.
There are two levels of scheduling criteria for psychotropic sub-
stances. At the ﬁrst level, in addition to similarity to scheduled sub-
stances, dependence liability, together with psychotropic effects is an
optional criterion. In applying this criterion, it is necessary to conﬁrm
that the substance in question has dependence liability and can pro-
duce “central nervous system stimulation or depression, resulting in
hallucinations or disturbances in motor function, thinking, behaviour,
perception or mood”. This criterion has enabled the scheduling of
new types of dependence-producing psychotropic substances that are
not similar to substances already scheduled. However, the scheduling
criteria for psychotropic substances, unlike those for narcotic drugs,
have an additional requirement for “evidence that the substance is
being or is likely to be abused so as to constitute a signiﬁcant public
health and social problem warranting the placing of the substance
under international control”. This provision has deterred this
Committee from proposing “preventive” controls for psychotropic
substances.
Further details of the scheduling criteria in the 1961 Convention
concern the scheduling of:
— preparations of narcotic drugs that can be exempted from certain
control measures, such as prescription requirements, (Schedule
III); and
— narcotic drugs that are particularly liable to abuse and are replace-
able for medical use (Schedule IV).
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Schedules are:
Schedule I morphine, hydromorphone
Schedule II codeine, dextropropoxyphene
Schedule III codeine tablets containing not more than 100mg/tablet
or a cough syrup containing not more than 2.5%
codeine
Schedule IV heroin, cannabis
The Guidelines also provide guidance for selecting an appropriate
schedule for psychotropic substances under the 1971 Convention, as
follows:
Schedule I Substances whose liability to abuse constitutes an espe-
cially serious risk to public health and which have very
limited, if any, therapeutic usefulness.
Schedule II Substances whose liability to abuse constitutes a sub-
stantial risk to public health and which have little to
moderate therapeutic usefulness.
Schedule III Substances whose liability to abuse constitutes a sub-
stantial risk to public health and which have moderate
to great therapeutic usefulness.
Schedule IV Substances whose liability to abuse constitutes a smaller
but still signiﬁcant risk to public health and which have
a therapeutic usefulness from little to great.
In cases where the above criteria apply only in part, the scheduling
recommendation should be made with a higher regard to the risk to
public health than to therapeutic usefulness.
Notwithstanding the above, recommendations for inclusion in Sched-
ule I should be made only when the above criteria are fully met, with
respect to both therapeutic usefulness and the risk to public health.
Examples of psychotropic substances in these Schedules under the
1971 Convention are:
Schedule I lysergide (LSD), N,a-dimethyl-3,4-(methlenedioxy)
phenethylamine (MDMA)
Schedule II amphetamines, methaqualone
Schedule III amobarbital, ﬂunitrazepam, buprenorphine, pentazo-
cine
Schedule IV diazepam, amfepramone
It should be noted that the ordering of the Schedules in the two
Conventions is not comparable. In the 1961 Convention, Schedule IV
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4is the most restrictive whereas it is the least restrictive in the 1971
Convention. Further confusion may be created by national regulatory
systems that use their own scheduling systems.
3. Critical review of psychoactive substances
3.1 Critical review
A critical review is conducted by the Expert Committee in any of the
following cases: (1) there has been notiﬁcation from a Party to the
1961 or the 1971 Convention concerning the scheduling of a
substance; (2) there has been an explicit request from the UN Com-
mission on Narcotic Drugs to review a substance; (3) pre-review of a
substance has resulted in a recommendation for critical review; (4)
information is brought to the attention of WHO that a substance of
especially serious risk to public health and society, and of no recog-
nized therapeutic use by any Member State is clandestinely manufac-
tured. If therapeutic use of the substance is conﬁrmed subsequently
by any Member State in respect of case (4), the substance shall be
subject to a pre-review.
All the ﬁve substances under critical review at the present meeting
were pre-reviewed at the previous meeting of the Committee (4) and
recommended for critical review.
3.2 Amfepramone (INN)
Substance identification
Amfepramone is chemically 2-(diethylamino)propiophenone (CAS
No. 90-84-6 for base, 134-80-5 for hydrochloride). It is also known
as diethylpropion. Amfepramone is marketed under many trade
names.
Previous review
Amfepramone was included in Schedule IV of the 1971 Convention at
the time of its adoption. It was reviewed by a WHO Review Group in
1980 (5), which concluded that there was no evidence to recommend
a change in the level of its international control. Amfepramone was
pre-reviewed at the previous meeting of the Committee (4) when a
critical review was recommended based on information from the
International Narcotics Control Board (INCB) that abuse and illicit
trafﬁcking of amfepramone had been reported from nearly all regions
of the world, and had become particularly widespread in Asia and the
Russian Federation.
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nervous system
Amfepramone is an anorectic amphetamine analogue used for treat-
ing obesity. It has a spectrum of pharmacological effects similar to
that of scheduled amphetamines, including the release of dopamine.
Dependence potential
Dependence on amfepramone can occur but there are few data avail-
able on its incidence. In some patients, tolerance to the anorectic
effects of the drug may occur within 6 to 12 weeks. Amfepramone has
been shown to produce euphoria and other mood changes character-
istic of drugs of abuse.
Actual abuse and/or evidence of likelihood of abuse
Information from INCB indicates that illicit trafﬁc in amfepramone
has been reported from many countries and regions. In several coun-
tries in South America, overuse of anorectic stimulants has led to
additional educational and regulatory actions being undertaken by
the authorities. However, the small number of adverse drug reaction
reports related to abuse received by the international drug monitor-
ing programme does not suggest a high liability of amfepramone to
abuse. The response of governments to the WHO questionnaire also
indicated that diversion and abuse of the drug were limited.
Therapeutic usefulness
Amfepramone has been used as an oral anorectic in the treatment of
obesity, although stimulants are not generally recommended for this
indication. The drug is indicated only as an adjunct to other forms of
therapy (such as caloric restriction, exercise and behaviour modiﬁ-
cation techniques). Some medicinal regulatory authorities in the
European Union have already withdrawn amfepramone from the
market because of concerns about its safety. The global consumption
of amfepramone has been decreasing since 1997, in line with the
decline in the total consumption of stimulants in Schedule IV of the
1971 Convention.
Recommendation
The Committee judged that according to the scheduling criteria set
out in the Guidelines, a psychotropic substance in Schedule IV of the
1971 Convention, such as amfepramone, should have a liability to
abuse that poses a “signiﬁcant” risk to public health. The Committee
did not recommend a change in the scheduling status of amfepramone
since the information available to it was insufﬁcient to justify placing
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tutes a “substantial” risk to public health. Law enforcement data on
the extent of illicit activities involving stimulants in other schedules of
the 1971 Convention may enable the risk of abuse of amfepramone to
be compared with abuse of other stimulants in the future. In the
meantime, in view of the existing concern about its safety in medical
use, the Committee recommended that informational and educa-
tional activities to curb its overuse be intensiﬁed.
3.3 Amineptine (INN)
Substance identification
Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-
yl)amino]heptanoic acid) is available as either the free base (CAS
57574-09-1) or as the hydrochloride salt (CAS 30272-08-3). There are
no chiral carbon atoms, therefore, no stereoisomers or racemates are
possible.
Previous review
Amineptine was pre-reviewed at the thirty-second meeting of the
Committee (4) and critical review was recommended.
Similarity to known substances and effects on the central
nervous system
Amineptine is a synthetic, atypical tricyclic antidepressant with stimu-
lating effects on the central nervous system. It is an indirect dopamine
agonist, which selectively inhibits dopamine uptake and induces
dopamine release, with additional stimulation of the adrenergic sys-
tem. Its antidepressant effects are similar to those of other tricyclic
antidepressant drugs but amineptine has a more rapid action, is better
tolerated and has few cardiovascular, analgesic or anorectic effects. It
produces a similar spectrum of pharmacological effects to the psycho-
motor stimulants in Schedule II of the 1971 Convention.
Dependence potential
There have been few animal studies on the potential for dependence
or abuse of amineptine. However, some clinical studies have indi-
cated that amineptine has the potential both for dependence and
abuse, particularly in patients with a previous history of substance
abuse. Members of the Committee reported on their observations of
signiﬁcant abuse and dependence in patients treated with amineptine
in France. The dependence potential of the drug appeared to be
associated with its psychomotor stimulant effect. The clinical manifes-
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tion and bulimia. Instances of dependence have been reported in Asia
and Europe.
Actual abuse and/or evidence of likelihood of abuse
Amineptine abuse has been reported mainly in Asia and Europe. The
drug has been withdrawn from the market in France, where it was
developed a few decades ago, because of its considerable hepatotox-
icity and abuse. However, its medical use in developing countries, as
well as its abuse continue. The reports of adverse drug reactions
collected by the international drug monitoring programme indi-
cated a larger number of case reports of abuse and dependence for
amineptine than for other anorectic stimulants currently placed
in Schedule IV of the 1971 Convention, such as amfepramone. The
responses of governments to the WHO questionnaire also indicated
limited diversion and abuse of the drug although some reported hos-
pital admissions have been linked to the use or abuse of amineptine.
Therapeutic usefulness
The therapeutic usefulness of amineptine is limited because of its
hepatotoxicity, secondary features such as acne eruption and anxiety,
and the availability of safer antidepressants. Of the 103 countries that
responded to the WHO questionnaire, only 17 indicated amineptine
use.
Recommendation
The Committee considered that the degree of risk to public health
and society associated with the abuse liability of amineptine is sub-
stantial and noted that its use is associated with signiﬁcant hepatotox-
icity. Its therapeutic usefulness has been assessed to be from little
to moderate, at best. Although it has already been withdrawn from
the market in several countries, amineptine continues to be available
in a number of others. The Committee therefore considered that the
likelihood of its abuse warranted its placement under international
control. The Committee recommended that amineptine be placed in
Schedule II of the 1971 Convention.
3.4 Buprenorphine (INN)
Substance identification
Buprenorphine is chemically 21-cyclopropyl-7-a-[(S)-1-hydroxy-1,2,
2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine
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marketed under at least 26 trade names.
Previous review
In 1983, a WHO Review Group did not recommend international
control of buprenorphine, although it recommended the inclusion of
pentazocine (a pharmacologically related substance) in Schedule III
of the 1971 Convention (6). A critical review of buprenorphine was
again undertaken at the twenty-ﬁfth meeting of the Committee (7),
which recommended its placement in Schedule III of the 1971 Con-
vention. However, other than the difference between the partial
m-opioid agonist buprenorphine and such prototypic m-opioid ago-
nists as heroin, morphine and methadone, the Committee did not
provide any additional explanation for the choice of the 1971 Conven-
tion over the 1961 Convention. In its report for 1995, INCB requested
a revision of the control system of buprenorphine by WHO. In con-
sideration of these issues and evidence of signiﬁcant abuse and
illicit trafﬁcking despite international control in Schedule III of the
1971 Convention, the Committee recommended critical review of
buprenorphine at its thirty-second meeting (4).
Similarity to known substances and effects on the central
nervous system
Buprenorphine is a partial m-opioid agonist and k-opioid receptor
antagonist. It has been widely marketed as an analgesic and more
recently has been used in the treatment of opioid dependence. As a
partial m-opioid agonist it produces pharmacological effects similar to
those of low-to-moderate doses of morphine and other full m-opioid
agonists, but has a signiﬁcantly lower maximal effect. Because of its
low intrinsic activity, high afﬁnity for, and slow dissociation from, the
m-opioid receptor it precipitates withdrawal syndrome in morphine-
dependent animals and humans. Furthermore, pretreatment with
buprenorphine attenuates the effects of morphine and other full
m-opioid agonists. For these reasons buprenorphine is both an opioid
agonist and an antagonist.
Dependence potential
Buprenorphine has reinforcing effects in animal studies, produces
euphoria and other positive mood changes in opioid abusers and
produces mild physical dependence. No studies published after the
twenty-ﬁfth meeting of the Committee (7) have suggested the need
for revising their earlier conclusion that buprenorphine does have
signiﬁcant dependence potential.
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Although buprenorphine is widely marketed, France and the United
Kingdom consume far more of the drug on a per capita basis than the
other countries. In France, where buprenorphine is the main mainte-
nance treatment for patients with opioid dependence that general
practitioners are allowed to prescribe, there have been reports of
diversion and abuse by polydrug abusers. Information from other
countries and INCB on diversion and abuse indicates that
buprenorphine is liable to be abused so as to constitute a substantial
risk to public health and society. Despite the diversion and abuse
of buprenorphine in France the number of deaths from opioid over-
dosage has decreased signiﬁcantly following the introduction of
buprenorphine substitution therapy. Overall, the risk–beneﬁt ratio
for the use of buprenorphine in the treatment of opioid dependence
was judged by the Committee to be favourable.
Therapeutic usefulness
Buprenorphine is currently used in about 60 countries as an analgesic
and in about 30 countries for substitution treatment of opioid depen-
dence. However, its use as a treatment for opioid dependence is
rapidly increasing.
Application of the Guidelines
The majority of the Members of the Committee considered that,
on the basis of the similarity criterion, buprenorphine should be re-
classiﬁed under the 1961 Convention. The Committee considered
that buprenorphine has greater similarity to morphine than to
lefetamine, the only analgesic drug controlled as a psychotropic
substance at the time the 1971 Convention was adopted. Although
lefetamine is an analgesic that binds to brain opioid receptors it was
abused during the 1950s in Japan for its stimulant effects on the
central nervous system.
The Committee also noted that the scheduling criterion for psycho-
tropic substances would apply to almost all drugs controlled under the
1961 Convention. Morphine and cocaine are clearly psychoactive
substances capable of producing stimulation or depression of the
central nervous system, “resulting in hallucinations or disturbances in
motor function, thinking, behaviour, perception or mood”. They are
also dependence-producing. Therefore, morphine and cocaine meet
the ﬁrst-level requirement for being scheduled as psychotropic sub-
stances. There is no authoritative guidance, in either the 1971 Con-
vention or in the Guidelines, as to which of the two optional criteria
the Committee should apply. The Committee was also informed that
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the Guidelines require stronger justiﬁcation for recommending a
change in the control status of a substance from one convention to
another.
Recommendation
For the reasons stated above, the Committee considered that the
ﬁnal decision on buprenorphine should be taken at a future meeting
of the Committee. The Committee also recommended that WHO, in
consultation with the United Nations, develop guiding principles for
making the choice between the two optional scheduling criteria for
psychotropic substances and elaborate the Guidelines with regard to
the choice of the more appropriate convention when a substance
under review has some similarity to both a psychotropic substance
and a narcotic drug. This issue is of particular relevance to the consid-
eration of changing the control of a substance from one convention to
the other.
3.5 Delta-9-tetrahydrocannabinol
Substance identification
Delta-9-tetrahydrocannabinol is chemically 6a,7,8,10a-tetrahydro-
6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol. Dronabinol
(CAS 1972-08-3) is the INN for one of the stereochemical variants of
delta-9-tetrahydrocannabinol, namely (-)-trans-delta-9-tetrahydro-
cannabinol.
Previous review
Delta-9-tetrahydrocannabinol was included in Schedule I of the 1971
Convention at the time of its adoption. At its twenty-sixth meeting,
the Committee recommended that dronabinol be moved to Schedule
II, while keeping the other isomers and their stereochemical variants
in Schedule I. This proposal was rejected by the Commission on
Narcotic Drugs, and the Committee reviewed the question again at its
twenty-seventh meeting when it recommended that all the stere-
ochemical variants of delta-9-tetrahydrocannabinol be rescheduled to
Schedule II (8). This recommendation was adopted by the United
Nations. At its thirty-second meeting, the Committee pre-reviewed
dronabinol and recommended its critical review for consideration of
the rescheduling on the grounds that the rate of abuse of dronabinol
was extremely low (4).
Untitled-55 3/17/2003, 2:46 PM10
11
Similarity to known substances and effects on the central
nervous system
Delta-9-tetrahydrocannabinol is the main active principle of cannabis
which is a well known psychotropic substance and exhibits the percep-
tion-altering effects possessed by cannabis.
Dependence potential
Although cannabis abuse is widespread, there is no evidence that
dronabinol shares the high abuse liability of cannabis.
Actual abuse and/or evidence of likelihood of abuse
In terms of abuse potential, there may not be any signiﬁcant differ-
ence between delta-9-tetrahydrocannabinol and cannabis, in which
this psychoactive substance occurs naturally. In terms of likelihood of
abuse, however, there is a very signiﬁcant difference between the two.
Cannabis abuse is widespread throughout the world whereas the
abuse of delta-9-tetrahydrocannabinol or of its preparations is rare.
Of the 103 countries that responded to the WHO Questionnaire, only
two indicated some abuse of this substance: Denmark reported some
abuse of “cannabinol”, clarifying that it meant the detection of delta-
9-tetrahydrocannabinol in the exhibit, and the questionnaire from the
USA mentioned three cases of abuse reported by the American
Association of Poison Control Centers during the period from 1992
to 1994.
Therapeutic usefulness
Dronabinol is indicated for the treatment of nausea and vomiting
associated with cancer chemotherapy in patients who have failed to
respond adequately to conventional antiemetic treatments and for the
treatment of anorexia associated with weight loss in patients with
acquired immunodeﬁciency syndrome (AIDS). Of the 103 countries
that responded to the WHO Questionnaire, only six reported
the regular availability of pharmaceutical products containing
dronabinol.
Recommendation
The abuse liability of dronabinol is expected to remain very low so
long as cannabis continues to be readily available. The Committee
considered that the abuse liability of dronabinol does not constitute
a substantial risk to public health and society. In accordance with
the established scheduling criteria, the Committee considered that
dronabinol should be rescheduled to schedule IV of the 1971 Con-
vention on Psychotropic Substances. To avoid placing different
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stereochemical variants of the same substance under different control
systems, the Committee recommended that all stereochemical vari-
ants of delta-9-tetrahydrocannabinol be moved to Schedule IV of the
1971 Convention.
3.6 Tramadol (INN)
Substance identification
Tramadol, chemically (+/-)trans-2-dimethylaminomethyl-1-(3-
methoxyphenyl) cyclohexanol), is available as either the free base
(CAS 27203-92-5) or as the hydrochloride salt (CAS 36282-47-0). It is
marketed under over 100 trade names.
Previous review
Tramadol was pre-reviewed at the twenty-eighth meeting of the Com-
mittee at which time critical review was not recommended (9); how-
ever following pre-review at the thirty-second meeting, critical review
was recommended (4).
Similarity to known substances and effects on the central
nervous system
Tramadol has been found to be an opioid agonist with selectivity for
the m-opioid receptor but with some weak afﬁnity for the k- and
d-opioid receptors. The afﬁnity for the m-opioid receptor is approxi-
mately 10-fold less than that of codeine and 6000-fold less than that of
morphine. The O-desmethyl metabolite (ODT or M1) of tramadol
has a 200-fold greater afﬁnity than the parent compound for the
m-opioid receptor. In addition to its actions on brain opioid receptors
tramadol is an inhibitor of serotonin reuptake (+ isomer) and of
noradrenaline reuptake (- isomer). Tramadol induces analgesia, but
is associated with less respiratory depression than other opioids and
has no signiﬁcant cardiac effects. It has been found to reduce the
seizure and sweating thresholds but reduces postoperative shivering.
Tramadol has been noted to have some effects on the central nervous
system, notably dizziness; sedation; headache and, to a lesser extent,
euphoria; central nervous system stimulation (e.g. tremor, agitation,
anxiety and hallucinations); dysphoria and seizures. In the 1% of
patients who suffered seizures, they were found to be linked to a
predisposing factor such as epilepsy, alcohol or drug withdrawal or
antidepressant therapy. Toxic effects can be produced directly by
the drug and these effects may be exacerbated by the presence of
monoamine antidepressant drugs or central nervous system depres-
sant drugs. Overdose has been reported to result in bradycardia,
convulsions, respiratory depression and coma.
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Dependence potential
Animal studies have indicated that tramadol produces little tolerance,
has mild withdrawal symptoms and a lower abuse potential than
codeine and pentazocine. Nevertheless, together with the rapid in-
crease in the medical use of tramadol worldwide, there have been
reports of dependence and abuse, particularly in opioid-dependent
individuals. The actions of the drug on brain monoamine systems
must also be considered in relation to its abuse potential.
Actual abuse and/or evidence of likelihood of abuse
Of the 103 countries that responded to the WHO Questionnaire, 88
indicated the medical use of tramadol. Of these, 21 reported some
abuse and illicit trafﬁc. The reported cases of abuse originated pri-
marily from Europe and the United States. Deaths from overdose
were reported from France and the United States. In a few of these
countries, abuse of tramadol has led to regulatory actions such as
temporary suspension of marketing registration or the use of special
prescription forms. However, the assessment of its abuse liability is
made difﬁcult by the scarcity of quantitative data and considerable
differences in the experiences of individual countries. In Germany
where the drug was developed and has been on the market for 25
years without additional controls other than prescription require-
ments, the data from the drug abuse warning system suggest that
tramadol has lower abuse liability than buprenorphine and pentazo-
cine. The data from the drug abuse warning network of the USA, on
the other hand, suggest that its abuse potential may be roughly com-
parable to that of codeine or dextropropoxyphene in the USA. The
regulatory authorities in the USA required that the sponsor of
tramadol set up an independent group of scientists to conduct post-
marketing studies of abuse of and dependence on tramadol. These
studies found that the rate of abuse in the year following the introduc-
tion of tramadol to the market was 2–3 cases per 100000 patients.
Subsequently, this rate declined to one case per 100 000. The adverse
drug reaction reports related to abuse of tramadol collected by the
international drug monitoring programme indicate larger numbers of
case reports of abuse, dependence and withdrawal syndrome for
tramadol than for any other analgesic, except butorphanol, which
ranks ﬁrst in the list of drugs for which “drug dependence” has been
reported. Many of these reports originated from the USA, where the
consumption of tramadol has been increasing rapidly since it was ﬁrst
marketed in 1995, a situation conducive to higher rates of reporting
adverse events.
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Therapeutic usefulness
Tramadol is used as an analgesic agent for the treatment of moderate
to severe pain. It became available in Germany in the 1970s and was
subsequently marketed in Africa, the Americas and Asia, and is
currently used in 104 countries. It is however difﬁcult to judge
whether the rapid increase in its medical use reﬂects the recognition
of its therapeutic usefulness. The absence of international control
may be a contributing factor.
Recommendation
Pharmacologically, tramadol is more complex than prototypic
m-opioid receptor agonists, but one of its metabolites is a potent
m-opioid receptor agonist. This is consistent with its pattern of abuse
which is similar to that of opioids by opioid abusers, as well as its
opioid-like analgesic effects. The likelihood of abuse of tramadol
appears to vary between countries, depending on the prevalence of
opioid dependence, types of marketing strategy and other factors.
The information available is not sufﬁcient for the Committee to rec-
ommend international control of tramadol, but is adequate to recom-
mend that WHO keep the drug under surveillance.
4. Pre-review of psychoactive substances
The review of psychoactive substances by WHO is carried out in two
steps. The ﬁrst step is referred to as pre-review; this is a preliminary
review carried out by the Committee to determine whether or not a
fully documented review (critical review) of the substance is required.
The criterion for judgement of whether critical review is necessary is
whether or not WHO has information that may justify the scheduling
of the substance. In the case of psychotropic substances, this requires
information on actual abuse of the drug causing signiﬁcant public
health and social problems in more than one country.
In addition to the Secretariat, any member of the Expert Committee
or any representative of the other organizations invited to participate
in the Expert Committee meeting can submit a proposal to pre-review
a substance together with supporting information. At the present
meeting, ketamine, zalepron and zopiclone were proposed by the
Secretariat while butorphanol and khat were proposed by a Member
of the Committee. The representative of the International Narcotics
Control Board proposed oripavine.
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4.1 Ketamine (INN)
Ketamine, chemical name (±)-2-(2-chlorophenyl)-2-(methylamino)
cyclohexanone, has not previously been reviewed by WHO.
Ketamine is indicated to provide anaesthesia for short diagnostic and
surgical procedures that do not require skeletal muscle relaxation. Its
use in veterinary medicine must also be considered in relation to its
control. Ketamine hydrochloride has been abused as a hallucinogen
for almost 30 years. The drug produces effects similar to those of
phencyclidine, but with a much shorter duration. Limited abuse by
medical personnel has been reported in a number of countries. In
recent years, the abuse of ketamine mixed with or presented as N,a-
dimethyl-3,4-(methylenedioxy) phenethylamine (MDMA) has raised
a serious concern in Europe. Ketamine abuse is reported from a
number of countries in Asia, Europe and North America and it has
already been placed under national control in several countries.
Recommendation
On the basis of the information presented above, the Committee
recommended critical review of ketamine at a future meeting.
4.2 Zaleplon (INN)
Zaleplon, chemical name 3¢-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)-
N-ethylacetanilide, has not previously been reviewed by WHO.
Zaleplon selectively binds to the brain alpha subunit of the GABAA
omega-1 receptor. Its pharmacological properties are similar to those
of zolpidem, and it is indicated for the short-term (2 to 4 weeks)
management of insomnia. It produces a benzodiazepine-type with-
drawal syndrome upon discontinuation of long-term use and studies
on subjective effects show its similarity to triazolam. Zaleplon has
been on the market for only a short time and the number of reports of
abuse-related adverse drug reactions received by the international
drug monitoring programme are as yet very few.
Recommendation
Although the abuse potential of this substance is considered to be
similar to that of zolpidem and triazolam, critical review was not
recommended at this stage as the information on actual abuse avail-
able to the Committee was insufﬁcient to conﬁrm the existence of
signiﬁcant public health and social problems in more than one coun-
try. However, the Committee recommended that WHO continue the
surveillance of zaleplon1.
1 One Member of the Committee (Professor M.S. Bourin) expressed his concern regarding
the potential for abuse of and dependence on zaleplon and felt that a critical review was
warranted.
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4.3 Zopiclone (INN)
Zopiclone, chemical name 4-methyl-1-piperazinecarboxylic acid ester
with 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-hydroxy-5H-pyrrolo[3,4-
b]pyrazin-5-one, was pre-reviewed at the twenty-ninth meeting of the
Committee in 1994 (10), which recommended continued surveillance,
but not a critical review.
The pharmacological proﬁle of zopiclone is similar to that of chlor-
diazepoxide. The pharmacological activity of zopiclone is believed to
be related to its binding to the benzodiazepine receptor complex.
Studies of abuse liability in animals and humans have indicated that
zopiclone has some abuse potential together with the capacity to
produce withdrawal syndrome upon its discontinuation. In terms of
the number of adverse drug reaction reports related to abuse received
by the international drug monitoring programme, zopiclone ranks
higher than nitrazepam and temazepam. Furthermore, the Commit-
tee was informed that the government of Switzerland had submitted
a formal notiﬁcation to the United Nations concerning the scheduling
of zopiclone.
Recommendation
In accordance with the Guidelines, the Committee recommended the
critical review of zopiclone.
4.4 Butorphanol (INN)
Butorphanol, chemical name (-)-17-(cyclobutylmethyl)morphinan-
3,14-diol, was reviewed by a WHO Review Group in 1981 (11) and
1983 (6), and at the twenty-ﬁfth meeting of the Committee (7), which
did not recommend international control.
Butorphanol is a synthetically derived opioid compound with mixed
agonist–antagonist properties at the m-opioid receptor. It exerts its
analgesic effect by acting as an agonist at the k-opioid receptors.
Butorphanol has a proﬁle of actions similar to those produced by
pentazocine. Two to three milligrams of parenterally administered
butorphanol produce analgesia and respiratory depression approxi-
mately equal to that caused by 10mg of morphine. There have been a
signiﬁcant number of reports of abuse, withdrawal syndrome and
dependence related to butorphanol and this drug ranks ﬁrst in the list
of all drugs for which drug dependence has been reported as an
adverse drug reaction to the WHO International Drug Monitoring
Programme. Most of these reports originated from Canada, Italy,
the United Kingdom and the USA. In Canada, drug-seeking behav-
iour has been reported in association with the use and abuse of
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butorphanol nasal spray. At least four countries have taken regula-
tory actions to control butorphanol, indicating that its abuse is consid-
ered as a signiﬁcant problem in more than one country.
Recommendation
On the basis of the above data the Committee recommended the
critical review of butorphanol.
4.5 Oripavine
Oripavine, O3-demethylthebaine, is a phenanthrene alkaloid con-
tained in species of the Papaver plant. It is a major metabolite of
thebaine.
Oripavine has not previously been reviewed by WHO in the context
of international control. However, in a WHO review of the depen-
dence potential of thebaine held in 1980 (12), oripavine was suggested
to be a metabolite of thebaine in animals possibly involved in the
dependence potential.
In recent years, large quantities of concentrate of poppy straw (de-
ﬁned as “all parts (except the seeds) of the opium poppy after mow-
ing”) containing oripavine as the main alkaloid has been produced,
traded and used for the production of opium alkaloids. It is an easy
industrial process to convert oripavine into thebaine through methy-
lation. Thebaine is in Schedule I of the 1961 Convention because it is
a precursor of codeine and morphine. For this reason, the convertibil-
ity of oripavine may meet the scheduling criteria for placing it in the
same Schedule as thebaine. However, the Commentary on the 1961
Convention indicates that the purpose of controlling drugs which are
convertible to scheduled narcotic drugs, is to prevent the abuse of the
narcotic drugs manufactured by the conversion process. Although
animal tests have shown that thebaine has some abuse potential, no
actual abuse of thebaine has been reported. It is therefore question-
able whether the convertibility criterion could be applied for the
scheduling of a substance when the drug produced by its conversion is
used only as a starting material for the manufacture of other narcotic
drugs. An additional problem is that there is no authoritative guid-
ance on how to distinguish between the criteria of the 1961 Conven-
tion concerning convertibility and the criteria introduced by the 1988
Convention (13) concerning the control of precursors. Since the
Guidelines do not provide any guidance on this question, the Com-
mittee was unable to recommend critical review of oripavine at this
stage.
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Recommendation
The Committee urged WHO to develop additional scheduling guide-
lines in consultation with appropriate bodies of the United Nations
for clarifying issues related to the conversion of precursors into
scheduled substances.
4.6 Khat
Khat or qat refers to the leaves and the young shoots of the plant
Catha edulis Forsk. It has not previously been reviewed by WHO in
the context of international control.
In many countries in Africa and the Arabian peninsula khat is tra-
ditionally consumed by chewing the tender leaves and stems. The
principal psychoactive substances contained in the khat leaves are
cathinone and cathine. Cathinone has been shown to have high abuse
potential, and is in Schedule I. Reports of actual abuse of cathine have
led to its being placed in Schedule III of the 1971 Convention. The
migration of users of khat has resulted in the spreading of khat use to
countries in other regions of the world. Khat is consumed at parties
where friends gather and hold conversations while smoking cigarettes
and drinking tea and soft drinks. The subjective effects of khat are
rewarding; however, khat use produces signiﬁcant toxic effects includ-
ing increased blood pressure, tachycardia, insomnia, anorexia, consti-
pation, a sense of general malaise, irritability, reactive depression,
migraine and impaired sexual potency in men. Khat is believed to be
dependence-producing. Cases of toxic psychosis and paranoia due to
khat have been described by a number of authors. Other reported
acute and chronic effects of khat include low birth weight in babies of
khat chewing women, reduced sperm count and motility, increased
risk of myocardial infarction and liver problems. In addition to the
reported health problems, the regular consumption of khat is also
associated with a variety of social and economic problems affecting
the consumers and their families. A number of countries in Africa,
Asia, Europe and North America have already placed khat under
national control.
Recommendation
The Committee considered that there was sufﬁcient information on
khat to justify a critical review.
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5. Terminology used in reporting abuse-related
adverse drug reactions
The main function of the WHO Programme for International Drug
Monitoring is to provide early warnings of drug-related problems,
including drug abuse, dependence and withdrawal syndrome. Since
the initiation of the Uppsala Monitoring Centre (UMC), nearly three
million reports of adverse drug events have been received from health
care professionals (reporters) from 69 different countries. Reports
are originally sent as text, and then coded to provide medically useful
terms. Unfortunately, the terms used by the reporters can be im-
precise or contained within a large body of text. To enable the
programme to provide early warnings, any terms that can possibly
have a value as a pointer to dependence are coded as “dependence”
to ensure that early signals are not missed.
There is a need for caution in the interpretation of the UMC data. At
present, health care professionals do not use terminology related to
drug abuse and dependence in a consistent manner. For example, the
selective serotonin reuptake inhibitors (SSRIs) are important psycho-
active substances where terminology possibly indicative of depen-
dence poses a major problem (see Annex). The use of broad terms
such as “drug discontinuation syndrome” instead of “withdrawal”
also hampers data coding and interpretation.
The International Classiﬁcation of Diseases (ICD) (14) is the most
widespread tool used in health epidemiology. While it is correct to say
that withdrawal and tolerance are neither required nor sufﬁcient for a
positive diagnosis of dependence syndrome, excessive emphasis on
this aspect can lead to the misconception that withdrawal is unrelated
to dependence.
Deﬁnitions should be consistent within WHO, but it must be recog-
nized that terms may be used differently for different purposes. The
terms used in reporting adverse drug reactions are intended to de-
scribe drug effects and to communicate them to patients and health
care professionals. Avoiding terms that may be confusing for non-
professionals as well as ensuring translatability into all languages are
particularly important.
It was agreed that the Secretariat and the UMC should continue to
work together to provide the best data to meetings of the Committee.
The Committee discussed the deﬁnition of terms and emphasized the
need for careful interpretation of the UMC data.
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6. Other matters
The Committee noted the striking number of reports on paroxetine
and “withdrawal syndrome” (see list of SSRIs in the Table in the
Annex). The representative of Consumers International reported
that a number of patients had experienced difﬁculty in withdrawing
from SSRIs in general. It was agreed that withdrawal was indeed a
problem in some patients, but there was a difference of opinion on the
degree of dependence that was involved, given the possibility that the
need for treatment of resistant or relapsing disease could make these
drugs indispensable for patient care. The Committee expressed con-
cern about the possibility of inappropriate prescribing resulting in the
risk of problems of withdrawal outweighing the beneﬁts of treatment
with SSRIs.
The Committee agreed that there was a possible therapeutic problem
with these drugs, but that there was no evidence of diversion of the
drug for abuse because SSRIs are so widely available. The Committee
recommended that SSRIs be placed on the agenda of the next Com-
mittee for consideration, not in the context of control, but to promote
education and information on the appropriate use of psychoactive
drugs.
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Annex
Terminology used in reporting abuse-related
adverse drug reactions
The Expert Committee on Drug Dependence (ECDD) has been
instrumental in developing appropriate terminology to aid under-
standing of the phenomena of drug dependence and abuse. At its
thirteenth meeting (1), ECDD had already proposed using drug
dependence to replace the terms drug addiction and drug habituation.
This proposal was accepted globally during the 1970s.
However, the ICD-10 (2) employed certain technical terms that were
slightly different from the conventional terms, such as withdrawal
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state instead of withdrawal syndrome or abstinence syndrome. This led
to the question of whether ICD-10 was entirely consistent with the
deﬁnition of drug dependence worked out by the ECDD during the
1960s. At its twenty-eighth meeting (3) the Committee discussed this
question and concluded that there was no inconsistency between the
deﬁnition of drug dependence adopted by this Committee and the
diagnostic guidelines for dependence syndrome developed by WHO
in conjunction with ICD-10. This clariﬁcation has apparently reduced
the conceptual confusion, at least among drug abuse researchers and
treatment experts. However, in the area of postmarketing surveil-
lance, which involves a much broader range of health professionals,
conceptual confusion is still commonplace. Such confusion is particu-
larly common with regard to the meaning of closely-related terms, as
outlined below.
Drug addiction and drug dependence
Although the term drug addiction was eliminated from the technical
terminology of WHO many years ago, it is still widely used as a
general term. For example, the word addictive is commonly used
to mean dependence-producing. Where drug addiction is used as a
technical term it seems to refer to severe cases of dependence. How-
ever, as there is no internationally accepted deﬁnition of addiction,
it is impossible to be certain in what way addiction differs from
dependence.
Drug abuse and drug dependence
From the above-mentioned deﬁnition of drug abuse, it is clear that
acceptable medical use of the drug, whether or not it results in drug
dependence, is not drug abuse. There are situations in which treat-
ment with a dependence-producing drug needs to be continued, even
after the patient has become dependent on it. In this case, drug
dependence may be reported as an adverse drug reaction, but not as
drug abuse. In this connection, it is also useful to stress that depen-
dence liability alone is not sufﬁcient reason for proposing the inter-
national control of a psychoactive drug. It is the abuse liability
(likelihood of abuse) of the drug that must be considered. It is neces-
sary to make the distinction between the abuse of a psychoactive
substance which tends to result in the deterioration of an individual’s
physical, psychological and social functioning, and its therapeutic use
which is intended to improve any or all of these. It is also known that
not all dependence-producing drugs are abused (e.g. caffeine is
dependence-producing but it is seldom abused).
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Drug abuse and drug maladministration
Drug abuse is deﬁned as “persistent or sporadic excessive drug use
inconsistent with or unrelated to acceptable medical practice”. Thus,
the intentional use of excessive doses, or the intentional use of thera-
peutic doses for purposes other than the indication for which the drug
was prescribed, is drug abuse. Misuse and non-medical use are
synonyms of drug abuse. However, inappropriate prescribing (e.g.
indiscriminate prescribing of antibiotics) or medication errors, if
accidental or unintended, should not be classiﬁed as drug abuse.
Such an inappropriate use of the drug should rather be considered as
drug maladministration. Drug maladministration can cause many
adverse reactions and it is a drug safety problem requiring an appro-
priate response, but it can rarely be a consequence of the normal
therapeutic use of a drug. It is therefore difﬁcult to imagine a situation
in which drug maladministration needs to be reported to the adverse
drug reaction database; it has to be addressed as a separate safety
issue.
Physical (physiological) dependence and drug dependence
The ECDD (3) recommended against the use of the term physical
(physiological) dependence for several reasons. Firstly, it noted that
the distinction between physical (physiological) dependence and psy-
chic (psychological) dependence was difﬁcult to make in clinical situ-
ations. Such a distinction would also be inconsistent with the modern
view that all drug effects are potentially understandable in biological
terms. The term physical (physiological) dependence was also con-
sidered to be confusing because clinicians often interpreted the
manifestation of withdrawal syndrome as evidence of both physical
dependence and drug dependence. (This is not the case, as explained
in more detail below.) Nonetheless, the term is still used to mean a
state of adaptation evidenced by the manifestation of withdrawal
syndrome upon discontinuation of the drug or the development of
tolerance or both.
Drug dependence and withdrawal syndrome
The simplest explanation of drug dependence is “a state in which the
individual has a need for repeated doses of the drug to feel good or to
avoid feeling bad”. This is consistent both with general public under-
standing and with the more sophisticated deﬁnition of drug depen-
dence used by the ECDD. The ICD-10 (2) emphasizes the loss of
control over one’s drug-seeking behaviour as the core concept of drug
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dependence and sets out diagnostic guidelines for dependence syn-
drome with six check-points. Two of them concern withdrawal state
and tolerance while the remaining four could be considered as differ-
ent manifestations of the state of dependence itself. For a positive
diagnosis of dependence syndrome, at least three of the six criteria
must be observed. Thus, even when both tolerance and withdrawal
occur, this is not sufﬁcient to meet the requirement for dependence
syndrome unless one of the remaining four criteria is met. Conversely,
even when both withdrawal and tolerance are absent, an individual
can still have dependence syndrome if three of the remaining four
requirements are met.
It is therefore correct to say that withdrawal and tolerance are neither
required nor sufﬁcient for a positive diagnosis of dependence syn-
drome. However, excessive emphasis on this can lead to the mis-
conception that withdrawal syndrome is unrelated to dependence.
A withdrawal state or syndrome is one of the six criteria of which at
least three must be met for a positive diagnosis of dependence
syndrome to be made. In other words, when withdrawal syndrome
exists, one-third of the requirement for a positive diagnosis of depen-
dence syndrome is met. Therefore, the notion that withdrawal is
unrelated to dependence is inconsistent with the ICD-10 diagnostic
guidelines.
SSRIs are an example of how a conceptual confusion over terminol-
ogy can affect proper reporting, interpretation and communication
of adverse drug reactions related to dependence. To avoid the asso-
ciation with dependence, an increasing number of researchers have
used a different term, discontinuation syndrome, instead of with-
drawal syndrome. The number of hits for discontinuation syndrome
in searches of the international medical literature began to increase,
relative to the occurrence of withdrawal syndrome, in 1997 after
a symposium on antidepressant discontinuation syndrome held
in 1996. In fact, dependence syndrome has been reported to the
Uppsala Monitoring Centre for all SSRIs through the same
postmarketing surveillance systems, although there are signiﬁcantly
fewer reports of dependence syndrome than of withdrawal syndrome.
Also, the proportion of reports of drug dependence in relation to
the number of reports of withdrawal syndrome varies considerably
between individual SSRIs from 26% for ﬂuoxetine to only 1%
for venlafaxine (according to the global adverse drug reaction
database of the Uppsala Monitoring Centre as of June 2002) (see
Table below).
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Drug name Withdrawal syndrome Drug dependence Ratio (%)
reports (ws) reports (dd) dd/ws
Fluoxetine 419 109 26.0
Sertraline 631 69 10.9
Mirtazapine 17 1 5.9
Fluvoxamine 69 4 5.8
Nefazodone 83 4 4.8
Paroxetine 2380 91 3.8
Citalopram 107 3 2.8
Venlafaxine 1185 13 1.1
Three SSRIs are among the 30 highest-ranking drugs in the list of
drugs for which drug dependence has ever been reported to the
Uppsala Monitoring Centre database; a total of 269 reports had been
received as of June 2002 (109 reports for ﬂuoxetine, 91 for paroxetine
and 69 for sertraline).
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